Evidence map›Paper›PMID 31945300›Full record

ArticleAmerican journal of respiratory and critical care medicine2020

Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.

Kelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L Rosenkranz, Elisa H Ignatius, Eric L Nuermberger, Laura Moran, Kathleen Donahue and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine-An Approach for Clinical Management.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Review
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis.European journal of drug metabolism and pharmacokinetics · 2024
    Review
  16. Article
  17. Reconsidering the Role of Isoniazid in Drug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2024
    Article
  18. Review
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Kelly E DooleyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9013-5256
Sachiko MiyaharaHarvard T. H. Chan School of Public Health, Boston, Massachusetts.
Florian von Groote-BidlingmaierTASK Applied Science and Stellenbosch University, Cape Town, South Africa.
Xin SunHarvard T. H. Chan School of Public Health, Boston, Massachusetts.
Richard HafnerDivision of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Susan L RosenkranzHarvard T. H. Chan School of Public Health, Boston, Massachusetts.
Elisa H IgnatiusDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Eric L NuermbergerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Laura MoranSocial & Scientific Systems, Inc., Silver Spring, Maryland; and.
Kathleen DonahueFrontier Science and Technology Research Foundation, Amherst, New York.
Susan SwindellsDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Naadira VankerTASK Applied Science and Stellenbosch University, Cape Town, South Africa.
Andreas H DiaconTASK Applied Science and Stellenbosch University, Cape Town, South Africa.
A5312 Study Team
Harvard University · USJohns Hopkins University · USStellenbosch University · ZAFrontier Science & Technology Research Foundation · USNational Institute of Allergy and Infectious Diseases · USSocial and Scientific Systems (United States) · USUniversity of Nebraska Medical Center · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaUM1AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI Shaun Barnabas, Anneke Catharina Hesseling · 2012 to 2026
$21.5M
Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
Mentoring Investigators in HIV and Tuberculosis Therapeutics ResearchK24AI150349 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOOLEY, KELLY E. · 2020 to 2025
$789k
NIAID NIH HHS K24 AI150349NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069521NIAID NIH HHS UM1 AI106701NIGMS NIH HHS T32 GM066691
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

early bactericidal activityinhA mutationisoniazid resistancephase 2 clinical trialtuberculosis

Identifiers

PMID31945300
PMCPMC7258626
OpenAlexW3000553795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.